# Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT	
NATURE OF CONVEYANCE:	Corrective Assignment to correct the Doc. Date: 06/28/1999 and Assignor: University Research Corporation previously recorded on Reel 017015 Frame 0131. Assignor(s) hereby confirms the assignment of certain patent and other intellectual property rights.	

## CONVEYING PARTY DATA

Name	Execution Date
University Research Corporation	06/28/1999

#### RECEIVING PARTY DATA

Name:	The University of Colorado Foundation, Inc.	
Street Address:	4740 Walnut Street	
City:	Boulder	
State/Country:	COLORADO	
Postal Code:	80306	

#### PROPERTY NUMBERS Total: 4

Property Type	Number
Patent Number:	5596434
Patent Number:	5637256
Patent Number:	5658493
Patent Number:	5543078

#### CORRESPONDENCE DATA

Fax Number:	(303)607-3600		
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.			
Phone:	303-607-3500		
Email:	jmesser@faegre.com		
Correspondent Name:	Faegre & Benson LLP, Customer #35657		
Address Line 1:	2200 Wells Fargo Center		
Address Line 2:	90 South Seventh Street		
Address Line 4:	Minneapolis, MINNESOTA 55402		

ATTORNEY DOCKET NUMBER:

500074562

61297-306226

# PATENT REEL: 017089 FRAME: 0041

\$160.00

CH

#### **Total Attachments: 9**

source=Not of Recordation for Correction#page1.tif source=Not of Recordation for Correction#page2.tif source=Not of Recordation for Correction#page3.tif source=Not of Recordation for Correction#page4.tif source=Not of Recordation for Correction#page5.tif source=Not of Recordation for Correction#page6.tif source=Not of Recordation for Correction#page7.tif source=Not of Recordation for Correction#page7.tif source=Not of Recordation for Correction#page8.tif source=Not of Recordation for Correction#page8.tif

······································		PATENT ASSIGNMENT	-	
lectronic Version tylesheet Version		01/13/2006 500071113		
SUBMISSION TYPE:		NEW ASSIGNMENT		
NATURE OF CONVEYANCE:		ASSIGNMENT		
CONVEYING PART				î
		Name	Execution Date	
University Resarch	Corporation		06/28/2005	
RECEIVING PARTY	/ DATA			
Name:	The University of	of Colorado Foundation, Inc.		
Street Address:	4740 Walnut St	reet		
City:	Boulder			
State/Country:	COLORADO			3
Postal Code:	80306			
FRUPERIT NUMB				
PROPERTY NUMB	Туре	Numb	er	
[ <del></del>	7 Type	596434	er	0.6.1.2.4
Property	7 Type		er	
Property Patent Number:	7 Type 55 56	596434		
Property Patent Number: Patent Number:	7 Type 55	596434 537256		
Property Patent Number: Patent Number: Patent Number:	7 Type 58 56 56 56	596434 637256 658493	er	
Property Patent Number: Patent Number: Patent Number: CORRESPONDEN Fax Number:	7 Type 58 56 56 56 58 58 58 58 58 58 58 58 58 58 58 58 58	596434 537256 658493 543078 3600		
Property Patent Number: Patent Number: Patent Number: Patent Number: CORRESPONDEN Fax Number: Correspondence w	7 Type 55 56 56 56 56 56 56 56 56 56 56 56 56 5	596434 637256 658493 543078 3600 Jail when the fax attempt is unsuccess.		
Property Patent Number: Patent Number: Patent Number: CORRESPONDEN Fax Number:	7 Type 55 56 56 56 56 55 55 55 55 55 55 55 55	596434 537256 658493 543078 3600 <i>Iail when the fax attempt is unsuccess</i> 500		
Property Patent Number: Patent Number: Patent Number: Patent Number: CORRESPONDEN Fax Number: Correspondence w Phone:	7 Type 55 56 56 56 56 56 56 56 56 56 56 56 56	596434 637256 658493 543078 3600 Jail when the fax attempt is unsuccess.		
Property Patent Number: Patent Number: Patent Number: Patent Number: CORRESPONDEN Fax Number: Correspondence w Phone: Email:	7 Type 55 56 56 56 56 56 56 56 56 56 56 56 56	596434 537256 558493 543078 3600 <i>lail when the fax attempt is unsuccess</i> 500 faegre.com Benson LLP, Customer #35657 s Fargo Center		
Property Patent Number: Patent Number: Patent Number: Patent Number: CORRESPONDEN Fax Number: Correspondence w Phone: Email: Correspondent Nar Address Line 1: Address Line 2:	7 Type 58 56 56 56 56 56 56 56 56 56 56 56 56 56	596434 537256 658493 543078 3600 <i>fail when the fax attempt is unsuccess</i> 500 faegre.com Benson LLP, Customer #35657 s Fargo Center Seventh Street		
Property Patent Number: Patent Number: Patent Number: Patent Number: CORRESPONDEN Fax Number: Correspondence w Phone: Email: Correspondent Nar Address Line 1:	7 Type 58 56 56 56 56 56 56 56 56 56 56 56 56 56	596434 537256 558493 543078 3600 <i>lail when the fax attempt is unsuccess</i> 500 faegre.com Benson LLP, Customer #35657 s Fargo Center		
Property Patent Number: Patent Number: Patent Number: Patent Number: CORRESPONDEN Fax Number: Correspondence w Phone: Email: Correspondent Nar Address Line 1: Address Line 2:	7 Type 58 56 56 56 56 56 56 56 56 56 56 56 56 56	596434 537256 658493 543078 3600 <i>fail when the fax attempt is unsuccess</i> 500 faegre.com Benson LLP, Customer #35657 s Fargo Center Seventh Street		
Property Patent Number: Patent Number: Patent Number: Patent Number: Patent Number: CORRESPONDEN Fax Number: Correspondence w Phone: Email: Correspondent Nar Address Line 1: Address Line 2: Address Line 4:	7 Type 58 56 56 56 56 56 56 56 56 56 56 56 56 56	596434 537256 558493 543078 3600 <i>lail when the fax attempt is unsuccess</i> 500 faegre.com Benson LLP, Customer #35657 s Fargo Center Seventh Street lls, MINNESOTA 55402		

ĺ

Total Attachments: 5
source=Assign from URC to CU Foundation#page1.tif
source=Assign from URC to CU Foundation#page2.tif
source=Assign from URC to CU Foundation#page3.tif
source=Assign from URC to CU Foundation#page4.tif
source=Assign from URC to CU Foundation#page5.tif
-

# ASSIGNMENT AND ASSUMPTION AGREEMENT

This Assignment and Assumption Agreement (this "Assignment"), dated effective as of June 30, 1999, is by and between University Research Corporation, a Colorado corporation ("Assignor") and The University of Colorado Foundation, Inc., a Colorado nonprofit corporation ("Assignee").

#### <u>Recitals</u>

A. Assignor was formed as a wholly-owned subsidiary of Assignee to serve as the corporate vehicle to commercially exploit faculty inventions at the University of Colorado.

B. Pursuant to this relationship, Assignee transferred to Assignor certain patent and other intellectual property rights, including the Ribozyme Technology rights, FLC Rights and SELEX<sup>TM</sup> / Spert Technology rights (as defined herein).

C. Assignor now desires to transfer certain of its assets back to its sole shareholder, Assignee, subject to the terms and conditions set forth herein.

#### <u>Agreement</u>

1. <u>Definitions</u>.

(a) "<u>Ribozyme Technology</u>" shall mean all inventions, improvements or other developments relating to ribozymes including the identification, manufacture, synthesis, delivery, use and enhancement or control of ribozymes transferred pursuant to the Assignment of Intellectual Property Rights in Ribozyme Technology, dated effective as of September 1, 1993 by and between the Regents of the University of Colorado and URC.

(b) <u>"FLC Rights"</u> shall mean those patent and other intellectual property rights relating to ferroelectric liquid crystals and related materials and products as set forth on Schedule A and Schedule B of the Technology License and Industrial Research Agreement, dated June 1, 1994, by and between URC and Displaytech, Inc.

(c) <u>"SELEX<sup>™</sup> / Spert Technology"</u> shall mean those patent and other intellectual property rights relating to Systematic Evolution of Ligands by Exponential Enrichment and Systematic Evolution of Polypeptides by Reverse Translation as set forth in Section I of the Restated Assignment and License Agreement, dated effective as of July 17, 1991 by and between URC and Nexstar Pharmaceuticals, Inc. 2. <u>Assignment</u>. For good and sufficient consideration, the receipt of which is hereby acknowledged, Assignor does hereby assign, transfer, convey and deliver to Assignee all of Assignor's right, title and interest in and to the assets described below.

(a) All of the rights of Assignor in and to the stock listed on <u>Schedule 1</u> hereto (the "Stock");

(b) All of the rights of Assignor in and to the agreements and contracts listed on <u>Schedule 1</u> hereto (the "Contract Rights"); and

(c) All of Assignor's right, title and interest in and to the Ribozyme Technology, the FLC Rights and the SELEX<sup>™</sup> / Spert Technology (collectively, the "Intellectual Property").

The Stock, Contract Rights and Intellectual Property are referred to collectively herein as the Assigned Property.

3. <u>Representations and Warranties of Assignor</u>. Assignor hereby represents and warrants to Assignee, its successors and assigns that: a) Assignor has full power and authority to enter into this Agreement; b) this Agreement is enforceable against Assignor in accordance with its terms; c) this Agreement does not violate any agreement or contract to which Assignor is a party or by which Assignor or the Assigned Property is bound; and d) the Assigned Property is not subject to any liens or encumbrances.

4. <u>Assumption of Obligations: Assignee's Indemnity</u>. In consideration for the transfer of assets contemplated hereby, Assignee hereby assumes all of the obligations of the Assignor arising from and after the date hereof under the Assigned Property. Assignee further agrees to indemnify and hold harmless Assignor from and against all obligations or liabilities arising out of the Assigned Property from and after the date hereof.

5. Agreement Relating to Royalties from the SELEX<sup>™</sup> / Spert Technology. Assignee also agrees to assume the obligation of URC to donate its share of SELEX-derived royalties to the new MCDB building as agreed to by URC in that certain memorandum, dated December 21, 1993, to Larry Gold from Charlie McCord and John Holloway relating to URC Policy on Royalty and Equity Distributions from NeXagen Proceeds.

6. <u>Further Assurances</u>. Assignor agrees to cooperate with Assignee in providing further information, undertaking further acts and executing further documents necessary or desirable to effect the terms of this Assignment.

7. <u>No Partnership</u>. It is not the intent of the parties to create a partnership or joint venture or to assume partnership responsibility or liability.

#46786 v3

2

8. <u>Amendments</u>. No variation, amendment modification or waiver of any of the terms or conditions hereof shall be deemed valid unless made in writing and signed by the parties hereto.

9. <u>Governing Law</u>. This Assignment shall be construed and interpreted in accordance with the laws of the State of Colorado.

10. <u>Schedules</u>. All Schedules attached hereto are hereby incorporated by reference and form part of this Assignment.

IN WITNESS WHEREOF, the parties have caused this Assignment to be executed in their respective corporate names by their duly-appointed officers identified below.

ASSIGNOR:

ASSIGNEE:

UNIVERSITY RESEARCH CORPORATION, a Colorado corporation

By: Name: Charles Title: President

THE UNIVERSITY OF COLORADO FOUNDATION, INC., a Colorado nonprofit corporation

By: \_ C1. McCord

Name: <u>Charles C1</u> Title: President

PATENT REEL: 017089 FRAME: 0047 STATE OF COLORADO ) ss.

COUNTY OF BOULDER

The foregoing instrument was acknowledged before me this  $\frac{1}{28}$  day of June, 1999, by of University Research as as Projident Corporation, a Colorado corporation.

Witness my hand and seal.

ary Public

My commission expires: 12-9 202

)

)

STATE OF COLORADO ) ss.

COUNTY OF BOULDER

The foregoing instrument was acknowledged before me this 2? day of June, 1999, by as <u>President</u> \_ of The

4

University of Colorado Foundation, Inc., a Colorado nonprofit corporation.

Witness my hand and seal.

Public Merning Rd. 4701 Merning Rd. Benthaud, CO 80513

My commission expires: 12-9-2000

## SCHEDULE 1

# Description of Assigned Property

#### Stock:

- 1. 46,188 shares of common stock in Ribozyme Pharmaceuticals, Inc.
- 2. 10,000 shares of common stock in Displaytech, Inc.

#### Contract Rights:

- 1. Restated Assignment and License Agreement, dated July 17, 1991 by and between Nexstar Pharmaceuticals, Inc. and University Research Corporation, including without limitation rights to any royalties thereunder.
- 2. License Agreement among the University of Colorado, University Research Corporation and United States Biochemical Corporation dated September 1, 1993
- 3. License Agreement among the University of Colorado, University Research Corporation and Ribozyme Pharmaceuticals, Inc. dated September 1, 1993
- 4. Technology License and Industrial Research Agreement, dated June 1, 1994 by and between University Research Corporation and Displaytech, Inc.
- 5. Agreement, dated July 29, 1994 by and among University of Colorado, University Research Corporation and the University of Colorado Foundation, Inc.

## PATENT REEL: 017089 FRAME: 0049

## **RECORDED: 01/30/2006**